ad system banner

Recent Posts

• Amylyx Secures Funding for Therapy Candidate AMX0035
• The Many Challenges of Getting Out
• Trial of WVE-004 in Patients With C9orf72 Mutations Begins Dosing
• Sperogenix Acquires Rights in China to Develop ABSK021
• Partnership Aims to Lower Out-of-Pocket Costs for Rare Disease Meds
• Masitinib, Given Early in ALS Course, Extends Life, Trial Data Show
• Enrollment in Phase 3 Masitinib Trial Expected to Soon Resume in France
• ALS Association, ‘Stronger as One,’ Adopts Unified Structure
• Nominations Open for 2022 Eurordis Black Pearl Awards
• Time Travel With ALS: What If We Could?